dow jones stock market


The September U.S. Dollar Index is trading at 96.72, up 0.62.

The U.S. dollar index is trading at the highs of the session.

Market chatter about a military coup in Turkey has caused modest disruptions in forex trading .

In other Forex Markets;
EUR/USD is trading at 1.1028, down 0.0077.
GBP/USD is trading at 1.3174, down 0.0175.
USD/JPY is trading at 104.65, down 0.49.
USD/CAD is trading at 1.2965, up 0.0056.
AUD/USD is trading at 0.7571, down 0.0040.


Posted-In: U.S. Dollar IndexFutures Forex Markets

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Related Articles Stock Index Futures Move Down on Reports of Coup in Turkey 5 Stocks That Had A Lot Of Social Chatter This Week With Low Investor Confidence

dow jones stock market: Tata Motors Ltd(TTM)


Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    I’ve been watching Tata Motors Ltd. (TTM) over the past few years with increasing interest. As India’s largest carmaker, it stands to benefit from the tenfold projected growth in the middle class in both India and China over the next decade.

dow jones stock market: Norwegian Cruise Line Holdings Ltd.(NCLH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Carnival have dropped 4.2% to $43.74 at 2:39 p.m. today, while Royal Caribbean Cruise (RCL) has tumbled 5.6% to $66.15, and Norwegian Cruise Line Holdings (NCLH) is off 4.3% at $38.63.

  • [By Teresa Rivas]

    Norwegian Cruise Lines (NCLH) was up nearly 7% on Wednesday afternoon, following its fourth-quarter earnings report.

    Norwegian said that it earned 56 cents a share, a penny ahead of analysts’ expectations. Revenue rose 8.5% to $1.13 billion, also squeaking past the $1.11 billion consensus estimate.


    For the full year, Norwegian said it expects to earn between $3.75 and $3.85 a share, with a midpoint a penny above the $3.79 average analyst estimate. It’s first-quarter EPS guidance of 36 cents also came in ahead of the 34-cent consensus.

    Instinet analyst Harry Curtiswrites that after recent missteps, it was “vital” for Norwegian’s forecast to meet expectations but not seem too optimistic, a balancing act he believes the company achieved.

    He reiterated a Buy rating and $52 price target on the stock:

    NCLHs 2017 EPS outlook ($3.75 to $3.85) brackets our forecast ($3.75) and the Streets ($3.79). However, we believe there could be upside to that range, given the positive booking and pricing trends so far this year. We remain positive on the shares of NCLH, which we believe should continue to outperform through 2017.


    Norwegian was recently up 6.8% to $51.49.

  • [By Monica Gerson]

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post its quarterly earnings at $2.31 per share on revenue of $338.86 million.

  • [By Dan Caplinger]

    The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable news from certain pockets of the market helped bolster investor confidence. Toll Brothers (NYSE:TOL), Lantheus Holdings (NASDAQ:LNTH), and Norwegian Cruise Line Holdings (NASDAQ:NCLH) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

dow jones stock market: Hawaiian Holdings, Inc.(HA)


Advisors’ Opinion:

  • [By Adam Levine-Weinberg]

    Not surprisingly, shares of Hawaii-focused airline company Hawaiian Holdings (NASDAQ:HA) fell last Wednesday, following Kelly’s comments about Southwest Airlines expanding to Hawaii. However, while Southwest’s entry into the Hawaii market could cause some short-term disruption, it isn’t likely to hurt Hawaiian Airlines’ positioning in the long run.

  • [By Adam Levine-Weinberg]

    While most of its fellow airline stocks were grounded last year, Hawaiian Holdings (NASDAQ:HA) soared to new heights. Shares of Hawaiian Airlines’ parent company rose 61% during 2016, according to data from S&P Global Market Intelligence.

  • [By Adam Levine-Weinberg]

    Investors had high expectations for Southwest Airlines (NYSE:LUV) and Hawaiian Holdings (NASDAQ:HA) leading up to their earnings reports last week. Between late June 2016 and mid-January, shares of Hawaiian Holdings climbed 50%. Southwest Airlines stock was close behind, with a gain of more than 35% over that period.

dow jones stock market: Inovio Pharmaceuticals, Inc.(INO)

Advisors’ Opinion:

  • [By Keith Speights]

    A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.

  • [By Ben Levisohn]

    Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:

    CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild

    Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.


    In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.

    Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s DNA-based vaccine approach is safe and can rapidly transition to human studies.

    Shares of Inovio Pharmaceuticalshave gained 4.3% to $9.24 at 2:50 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.3% to $284.29.

  • [By Lisa Levin]

    Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were also up, gaining 24 percent to $8.84 following announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response.

  • [By William Patalon III]

    In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

Leave a Reply

Your email address will not be published. Required fields are marked *